These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 20414200

  • 1. Adaptive trials receive boost.
    Jones D.
    Nat Rev Drug Discov; 2010 May; 9(5):345-8. PubMed ID: 20414200
    [No Abstract] [Full Text] [Related]

  • 2. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D.
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [Abstract] [Full Text] [Related]

  • 3. Slow start to phase 0 as researchers debate value.
    Twombly R.
    J Natl Cancer Inst; 2006 Jun 21; 98(12):804-6. PubMed ID: 16788150
    [No Abstract] [Full Text] [Related]

  • 4. The role of the National Cancer Institute in drug development.
    Doroshow J.
    Clin Adv Hematol Oncol; 2005 Apr 21; 3(4):257-8. PubMed ID: 16166997
    [No Abstract] [Full Text] [Related]

  • 5. Japan works to shorten "drug lag," boost trials of new drugs.
    Sinha G.
    J Natl Cancer Inst; 2010 Feb 03; 102(3):148-51. PubMed ID: 20107160
    [No Abstract] [Full Text] [Related]

  • 6. Drug development process for a product with a primary pediatric indication.
    Allen AJ, Michelson D.
    J Clin Psychiatry; 2002 Feb 03; 63 Suppl 12():44-9. PubMed ID: 12562061
    [Abstract] [Full Text] [Related]

  • 7. Expanded clinical trials of treatments for multiple sclerosis: copolymer 1 (COP-1) treatment investigational new drug (IND) program.
    Stark Y.
    Ann Neurol; 1994 Jul 03; 36(1):114-5. PubMed ID: 8024251
    [No Abstract] [Full Text] [Related]

  • 8. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
    Schultheis LW, Rappaport BA.
    Anesth Analg; 2007 Mar 03; 104(3):479-80. PubMed ID: 17312189
    [No Abstract] [Full Text] [Related]

  • 9. Expanded clinical trials of treatments for multiple sclerosis. The Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis of The National Multiple Sclerosis Society.
    Whitaker JN.
    Ann Neurol; 1993 Dec 03; 34(6):755-6. PubMed ID: 8250523
    [No Abstract] [Full Text] [Related]

  • 10. Controversy trails adaptive clinical trials.
    Goozner M.
    J Natl Cancer Inst; 2012 Sep 19; 104(18):1347-8. PubMed ID: 22984199
    [No Abstract] [Full Text] [Related]

  • 11. Competitors try collaboration to speed drug development.
    Patlak M.
    J Natl Cancer Inst; 2010 Jun 16; 102(12):841-3. PubMed ID: 20530762
    [No Abstract] [Full Text] [Related]

  • 12. Executive summary from the final reports of the National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS.
    Oncology (Williston Park); 1991 Apr 16; 5(4):16, 18-9. PubMed ID: 1831034
    [No Abstract] [Full Text] [Related]

  • 13. Business barriers slowing the pace of cancer immunotherapy research and development.
    Tuma RS.
    J Natl Cancer Inst; 2007 Nov 07; 99(21):1570-3. PubMed ID: 17971521
    [No Abstract] [Full Text] [Related]

  • 14. Innovative strategies for early clinical R&D.
    Butz RF, Morelli G.
    IDrugs; 2008 Jan 07; 11(1):36-41. PubMed ID: 18175261
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Oncology's first Phase 0 trial.
    Rowan K.
    J Natl Cancer Inst; 2009 Jul 15; 101(14):978-9. PubMed ID: 19584322
    [No Abstract] [Full Text] [Related]

  • 17. FR-901228 Fujisawa/National Cancer Institute.
    Vigushin DM.
    Curr Opin Investig Drugs; 2002 Sep 15; 3(9):1396-402. PubMed ID: 12498018
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.